SORF CONSTRUCTS AND MULTIPLE GENE EXPRESSION CROSS-REFERENCES TO RELATED APPLICATIONS [0001] This application claims the benefit of US Provisional Patent Application Serial 61/256,544 filed October 30, 2009 by Gerald R. Carson et al., which is incorporated herein by reference in entirety. STATEMENT ON FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] Not applicable REFERENCE TO SEQUENCE LISTING, A TABLE, OR A COMPUTER PROGRAM LISTING COMPACT DISK APPENDIX [0003] Not Applicable (sequence listing provided but not as compact disk appendix) BACKGROUND [0004] In the field of recombinant expression technology, the achievement of high production levels of desired protein products and the ability to generate products of desired purity represent ongoing challenges. Such challenges are particularly relevant for protein products including biological therapeutics which are antibodies, but advances in this field also have relevance to other biologicals. Certain embodiments of the present invention at least in part address one or more aspects of these challenges. SUMMARY [0005] The following abbreviations are applicable: ORF, open reading frame; sORF, single open reading frame; MW, molecular weight; HC or H, immunoglobulin heavy chain; LC or L, immunoglobulin light chain; pab, Pyrococcus abyssi; pfu, Pyrococcus furiosus; pho, Pyrococcus horikoshii 0T3; aa or AA, amino acid(s); SP, signal peptide; LCSP, light chain signal peptide; MTX, methotrexate. 2 [0006] Embodiments of the invention generally relate to expression cassettes, vector constructs, recombinant host cells and methods for the recombinant expression and processing, including post-translational processing, of recombinant polyproteins and pre-proteins. in embodiments, one or more expressed products are immunoglobulins. [0007] In embodiments, the expression vectors comprise one or more intein segments. In embodiments, the intein segments are derived from one or more Ion inteins of organisms Pyrococcus abyssi, Pyrococcus fuiiosus, and Pyrococcus horikoshii 0T3. [0008] In embodiments, the architecture of a construct is configured with respect to the order and presence or absence of certain elements. In an embodiment, the order of certain vector gene segments is HL, where H and L indicate an immunoglobulin heavy and light chain respectively. In another embodiment, the order is LH. In a particular embodiment, the construct has a design labeled as (-) where the minus sign indicates that the construct has one signal peptide at the beginning of the ORF and a methionine inserted between the last amino acid of the intein and the first amino acid of the second protein subunit, e.g., a mature antibody chain following the intein. In a particular embodiment, the construct has a design labeled as (+) where the plus sign indicates the presence of a first signal peptide at the beginning of the ORF and a second signal peptide at the beginning of the second protein subunit downstream of the intein. In a particular embodiment the configuration is HL(-). [0009] In embodiments, the invention provides sORF (single open reading frame) constnjct designs capable of producing levels of protein expression which are greater than 2, 5,10, 20, 30, 40, or 50 microgams per ml of secreted product when measured in culture supematants from experiments under transient expression conditions. In embodiments, the invention provides sORF constructs capable of producing levels of protein expression which are greater than 20 micrograms per ml per day when measured in culture supematants from experiments with conditions using a stable CHO (Chinese hamster ovary) cell expression system. In an embodiment, the expression level (pg/ml/day) is in the range of 1 to 24, greater than 10, or greater than 20. In a particular embodiment, the expression level is 24 3 pg/ml/day. In embodiments, the protein expression is of secreted antibody wfiich has self-assembled into a multimeric unit of heavy and light chains. In embodiments, the antibody is of an IgG isotype. [00010] In an emtxxliment, the invention provides an isolated or purified expression vector for generating one or more recombinant protein products comprising a single open reading frame insert; said insert comprising: (a) a signal peptide nucleic acid sequence encoding a signal peptide; (b) a first nucleic acid sequence encoding a first polypeptide; (c) a first intervening nucleic acid sequence encoding a first protein cleavage site, wherein said first protein cleavage site is provided by an intein segment of a Ion protease gene of Pyrococcus or a kIbA gene of Pyrococcus or Methanococcus, or a modified intein segment derived therefrom; and (d) a second nucleic acid sequence encoding a second polypeptide; wherein said first intervening nucleic acid sequence encoding said first protein cleavage site is operably positioned between said first nucleic acid sequence and said second nucleic acid sequence; wherein said signal peptide nucleic acid sequence encoding said signal peptide is operably positioned before said first nucleic acid sequence; and wherein said expression vector is capable of expressing a single open reading frame polypeptide cleavable at said first protein cleavage site. [00011] For clarity in the context of embodiments comprising various intervening segments and methods, an intervening nucleic acid sequence encoding a protein cleavage site can be such that the intervening nucleic acid sequence encodes at least a first protein cleavage site. In canonical inteins, for example, the cleavage reaction generally proceeds in an autoprocessive and rapid manner. A further explanation is in part dependent on the understanding of underlying mechanisms. From the post-processing perspective looking at the extein components, it can be understood that there is a first protein cleavage site and a second protein cleavage site toward the N-terminus and C-terminus of the intein segment, respectively. The designation of the cleavage sites is not intended to necessarily con'espond to the order in which cleavage reactions may occur, and it is recognized that there can be a perception of the cleavage reaction to be a single and relatively coordinated event at 4 one cleavage reaction site even if there is an appreciation of kinetically distinct steps in a given meclianism. This description also provides for embodiments of compositions and methods, as would be understood in the art, with intervening segments comprising one or more cleavage sites. Again depending on the understanding of processing mechanisms, a segment comprising one cleavage site or two cleavage sites can each allow for partial or complete excision of an intervening segment. [00012] In an embodiment, an intervening nucleic acid sequence further encodes a second protein cleavage site. [00013] In an embodiment of an expression vector, the first protein cleavage site is provided by an intein segment of a Ion protease gene of Pyrococcus abyssi, Pyrococcus furiosus, or Pyrococcus horikoshii 0T3; or an intein segment of a kIbA gene of Pyrococcus abyssi, Pyrococcus furiosus, or Mettianococcus jannascliii; or a modified intein segment derived respectively therefrom. [00014] In an embodiment, the intein segment or modified intein segment encodes a penultimate residue which is a lysine, serine or not a histidine. In an embodiment, the intein segment or modified intein segment is capable of cleavage but not complete ligation of said first polypeptide to said second polypeptide. [00015] In an embodiment, the first protein cleavage site is provided by an intein segment comprising a sequence selected from the group consisting of SEQ ID NO: 1, 3,4, 6, 7, 55, 35, 37, and 39 and modified intein segments derived therefrom. [00016] In an embodiment, the first polypeptide and second polypeptide are capable of multimeric assembly. In an embodiment, at least one of said first polypeptide and second polypeptide are capable of extracellular secretion. In an embodiment, at least one of said first polypeptide and second polypeptide are of mammalian origin. In an embodiment, the first polypeptide comprises an immunoglobulin heavy chain or functional fragment thereof, and said second polypeptide comprises an immunoglobulin light chain or functional fragment thereof, and said first polypeptide is upstream of (5' to) said second polypeptide. 5 [00017] In an embodiment of an expression vector, the vector comprises only one signal peptide nucleic acid sequence. [00018] In an embodiment, an expression vector further comprises a third nucleic acid sequence encoding a third polypeptide, and a second intervening nucleic acid sequence encoding a second protein cleavage site; wherein the second intervening nucleic acid sequence and third nucleic acid sequence, in that order, are operably positioned after said second nucleic acid sequence. [00019] In an embodiment of an expression vector, the first and said second polypeptide comprise a functional antibody or other antigen recognition molecule; with an antigen specificity directed to binding an antigen selected from the group consisting of: tumor necrosis factor-a, erythropoietin receptor, RSV, EL/selectin, interleukin-1, interleukin-12, interleukin-13, interleukin-17, interleukin-18, interleukin-23, interleukin-33, CD81, CD19, IGF1, IGF2, EGFR, CXCL-13, GLP-1R, prostaglandin E2, and amyloid beta. [00020] In an embodiment of the invention, for an expression vector the first and second polypeptides comprise a pair of immunoglobulin chains from an antibody of D2E7, EL246, ABT-007. ABT-325, or ABT-874. In an embodiment, the first and second polypeptide are each independently selected from an immunoglobulin heavy chain or an immunoglobulin light chain segment from an analogous segment of D2E7. EL246, ABT-007, ABT-325, ABT-874, or other antibody. [00021] In an embodiment, an expression vector further comprises a promoter regulatory element for said insert. In an embodiment, the promoter regulatory element is inducible or constitutive. In an embodiment, the promoter regulatory element is tissue specific. In an embodiment, the promoter comprises an adenovirus major late promoter. [00022] In an embodiment, the invention provides a host cell comprising a vector described herein. In an embodiment, the host cell is a prokaryotic cell. In an embodiment, the host cell is Escherichia coli. In an embodiment, the host cell is a eukaryotic cell. In an embodiment, the eukaryotic cell is selected from the group consisting of a protist cell, animal cell, plant cell, and fungal cell. In an embodiment, the eukaryotic cell is an animal cell selected from the group consisting of a 6 mammalian cell, an avian cell, and an insect cell. In an embodiment, the host cell is a mammalian cell line. In an embodiment, the host cell is a CHO cell or a dihydrofolate reductase-deficient CHO cell. In an embodiment, the host cell is an HEK (human embryonic kidney) cell or an African green monkey kidney cell, e.g., a COS cell. In an embodiment, the host cell is a yeast cell. In an embodiment, the yeast cell is Saccharomyces cerevisiae. In a embodiment, the host cell is a Spodoptera frugiperda Sf9 insect cell. [00023] In an embodiment, the invention provides a method for producing a recombinant polyprotein or a plurality of proteins, comprising culturing a host cell in a culture medium under conditions sufficient to allow expression of a vector protein. In an embodiment, the method further comprises recovering and/or purifying said vector protein. In an embodiment of a production method, the plurality of proteins are capable of multimeric assembly. In an embodiment, the recombinant polyprotein or plurality of proteins are biologically functional and/or therapeutic. [00024] In an embodiment, the invention provides a method for producing a recombinant product, wherein the product is an immunoglobulin protein or functional fragment thereof, assembled antibody, or other antigen recognition molecule, comprising culturing a host cell in a culture medium under conditbns sufficient to produce the recombinant product. In an embodiment, the invention provides a protein or polyprotein produced according to a method described herein. In embodiment, the invention provides an assembled immunoglobulin; assembled other antigen recognition molecule; or individual immunoglobulin chain or functional fragment thereof produced according to a method herein. In an embodiment, regarding the immunoglobulin; other antigen recognition molecule; or individual immunoglobulin chain or functional fragment thereof, there is a capability to effector contribute to specific antigen (where an antigen may be a ligand or counten-eceptor, etc.) binding to tumor necrosis factor-a, erythropoietin receptor, RSV, EL/selectin, interleukin-1, interleukin-12, interleukin-13, interleukin 17, interleukin-18, interleukin-23, interleukin-33. CD81, CD19, IGF1, IGF2, EGFR, CXCL-13, GLP-1R, prostaglandin E2 or amyloid beta. In an embodiment, the immunoglobulin or functional fragment thereof is the immunoglobulin D2E7 or ABT-874 or the functional fragment is a fragment respectively thereof. 7 [00025] In an embodinnent, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a protein and a pharmaceutically acceptable can-ier. [00026] In an embodiment, the invention provides an expression vector as described herein further comprising a nucleic acid sequence encoding a tag. In an embodiment of a vector construct, the intervening nucleic acid sequence additionally encodes a tag. [00027] In an emtxxJiment, the first and said second polypeptide comprise a functional antibody or other antigen recognition molecule; with an antigen specificity directed to binding an antigen selected from the group consisting of: tumor necrosis factor-a, erythropoietin receptor, RSV, EL/selectin, interleukin-1, interleukin-12, interleukin-13, interleukin-17, interleukin-18, interleukin-23, interleukin-33, CD81, CD19, IGF1, IGF2, EGFR, CXCL-13. GLP-1R, prostaglandin E2, and amyloid beta. In an embodiment, the first and second polypeptides comprise a pair of immunoglobulin chains from an antibody of D2E7, EL246, ABT-007, ABT-325, or ABT-874. In an embodiment, the first and second polypeptide are each independently selected from an immunoglobulin heavy chain or an immunoglobulin light chain segment from an analogous segment of D2E7, EL246, ABT-007, ABT-325, ABT-874, or other antibody. [00028] In an emtx)diment, a vector further comprises a promoter regulatory element for said sORF insert. In an embodiment, said promoter regulatory element is inducible or constitutive. In.an embodiment, said promoter regulatory element is tissue specific. In an embodiment, said promoter comprises an adenovirus major late promoter. [00029] In an embodiment, a vector further comprises a nucleic acid encoding a protease capable of cleaving said first protein cleavage site. In an embodiment, said nucleic acid encoding a protease is operably positioned within said sORF insert; said expression vector further comprising an additional nucleic acid encoding a second cleavage site located between said nucleic acid encoding a protease and at least one of said first nucleic acid and said second nucleic acid. 8 [00030] In an embodiment, the invention provides a host cell comprising a vector described herein. In an embodiment, the host cell is a prokaryotic cell. In an embodiment, said host cell is Escherichia coli. In an embodiment, said host cell is a eukaryotic cell. In an embodiment, said eukaryotic cell is selected from the group consisting of a protist cell, animal cell, plant cell and fungal cell. In an embodiment, said eukaryotic cell is an animal cell selected from the group consisting of a mammalian cell, an avian cell, and an insect cell. In a preferred embodiment, said host cell is a CHO cell or a dihydrofolate reductase-deficient CHO cell. In an embodiment, said host cell is a COS cell. In an embodiment, said host cell is a yeast cell. In an embodiment, said yeast cell is Saccharomyces cerevisiae. In an embodiment, said host cell is an insect Spodoptera frugiperda Sf9 cell. In an embodiment, said host cell is a human embryonic kidney cell. [00031] In an embodiment, the invention provides a method for producing a recombinant polyprotein or a plurality of proteins, comprising culturing a host cell in a culture medium under conditions sufficient to allow expression of a vector protein. In an embodiment, the method further comprises recovering and/or purifying said vector protein. In an embodiment, said plurality of proteins are capable of multimeric assembly. In an embodiment, the recombinant polyprotein or plurality of proteins are biologically functional and/or therapeutic. [00032] In an embodiment, the invention provides a method for producing an immunoglobulin protein or functional fragment thereof, assembled antibody, or other antigen recognition molecule, comprising culturing a host cell according to claim 38 in a culture medium under conditions sufficient to produce an immunoglobulin protein or functional fragment thereof, assembled antibody, or other antigen recognition molecule. [00033] In an embodiment, the invention provides a protein or polyprotein produced according to a method herein. In an embodiment, the invention provides an assembled immunoglobulin; assembled other antigen recognition molecule; or individual immunoglobulin chain or functional fragment thereof produced according to the methods herein. In an embodiment, the immunoglobulin; other antigen recognition molecule; or individual immunoglobulin chain or functional fragment thereof has a capability to effect or contribute to specific antigen binding to tumor 9 necrosis factor-a, erythropoietin receptor, interleukin-18, EL/selectin or interleul